NIH Logo
July 27, 2018
Volunteers
Healthy Volunteers Needed

Vaccine Research Center researchers seek healthy volunteers, 18-60 years old, for a study evaluating the dosage of two investigational products that target HIV. Compensation is provided. There is no risk of infection. For more information, call 1-866-833-5433, email vaccines@nih.gov or visit niaid.nih.gov/about/vrc.


Are You at Risk for Breast Cancer?

NCI is seeking women who are at risk for developing breast cancer. Researchers want to learn more about how certain cells progress to breast cancer. There is one screening visit and one study visit to the Clinical Center to collect cells within the breast ducts. Compensation is provided. More information: Office of Patient Recruitment, 1-866-444-2214 (TTY 1-866-411- 1010). Read about the study at http://go.usa.gov/chSFC. Refer to study 02-C-0077.

Patients with ME/CFS Needed

NINDS researchers are seeking individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) where persistent fatigue started after recovery from an infection. Study participation includes an initial inpatient visit of 5-10 days with up to 8 hours of testing each day. Some participants will be eligible for a second exercise stress study inpatient visit of 5-10 days with up to 8 hours of testing each day and overnight measurement at the Clinical Center. No cost for study-related tests and procedures and you may receive compensation for your participation. For more information, call 1-866-444-2214 (TTY 1-866-411-1010) and refer to study 16-N-0058. Read more at https://go.usa.gov/xQmWj.


NCCIH Seeks Healthy Volunteers

NCCIH is seeking healthy volunteers 12 and older to participate in a pain perception research study. Compensation is provided. To learn how to participate, call the Office of Patient Recruitment at 1-866-444-2214 (TTY 1-866-411-1010) or email cc-prpl@cc.nih.gov. Refer to study 16-AT-0077. Read more online at https://go.usa.gov/xQZkr.

Volunteers with Leukemia Needed

NHLBI researchers need volunteers with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL) for a new investigational treatment study. Researchers are adding pembrolizumab (an immunotherapy agent) to standard treatment. If you have received treatment for CLL and progressed or have high-risk genetic changes, such as deletion 17p, TP53 mutation, NOTCH1 mutation or complex cytogenics, you may be interested in participating. To learn more, call the Office of Patient Recruitment at 1-866-444-2214 (TTY 1-866-411-1010). Read more online at https://go.usa.gov/xQ7RY. Refer to study 17-H-0118.

back to top of page